HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.

Abstract
We evaluated the effectiveness of targeted cytotoxic analog of somatostatin (SST) AN-238, consisting of 2-pyrrolinodoxorubicin (AN-201) linked covalently to SST octapeptide carrier RC-121 in DU-145 human androgen-independent prostate cancers xenografted into nude mice. We also investigated the expression of mRNAs for SST receptor subtypes 2A and 5 (sst2A and sst5) in DU-145 tumors. After 8 weeks of treatment, AN-238 practically arrested the proliferation of DU-145 cancers. The tumor volume in nude mice that received 4 injections of AN-238 at the dose of 150 nmol/kg was 63.4+/-6.7 mm3, nearly 4 times smaller than that in controls which measured 249.1+/-36.3 mm3 (p<0.001). Treatment with AN-238 lowered tumor weight by 68% (p<0.01) compared with the control group and extended the tumor volume doubling time to 184.1+/-69.4 days, versus 32.1+/-6.6 days in controls (p<0.05). No toxicity-related deaths occurred during treatment with AN-238. Cytotoxic radical AN-201 administered alone or in an unconjugated mixture with carrier RC-121 inhibited the growth of DU-145 tumors only after the third and fourth injection and was toxic. The expression of mRNA for sst2A and sst5 was detected in all specimens of control DU-145 tumors and in tumors treated with AN-238. The present study demonstrates the high efficacy of SST-receptor-targeted chemotherapy in a model of human androgen-independent prostatic carcinoma.
AuthorsArtur Plonowski, Andrew V Schally, Attila Nagy, Baodong Sun, Gabor Halmos
JournalInternational journal of oncology (Int J Oncol) Vol. 20 Issue 2 Pg. 397-402 (Feb 2002) ISSN: 1019-6439 [Print] Greece
PMID11788908 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • AN 238
  • Antibiotics, Antineoplastic
  • Cytotoxins
  • Pyrroles
  • RNA, Messenger
  • RNA, Neoplasm
  • AN 204
  • Doxorubicin
  • RC 121
  • Octreotide
Topics
  • Animals
  • Antibiotics, Antineoplastic (pharmacology, therapeutic use)
  • Cell Division (drug effects)
  • Cytotoxins (pharmacology, therapeutic use)
  • Doxorubicin (analogs & derivatives, pharmacology, therapeutic use)
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Male
  • Mice
  • Mice, Nude
  • Neoplasm Transplantation
  • Neoplasms, Experimental (drug therapy, pathology)
  • Octreotide (analogs & derivatives, pharmacology)
  • Prostatic Neoplasms (drug therapy, pathology)
  • Pyrroles (pharmacology, therapeutic use)
  • RNA, Messenger (genetics, metabolism)
  • RNA, Neoplasm (genetics, metabolism)
  • Reverse Transcriptase Polymerase Chain Reaction
  • Treatment Outcome
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: